Highly Potent Active Pharmaceutical Ingredients

Remote Access Only Announcement

Due to ongoing concerns over COVID-19 we have now made this conference a virtual event. All speakers, attendees and sponsors will be able to access the full conference and its materials and will be able to log on remotely via the internet. Please contact a member of the SMi Team for more information [email protected]

This event will address the biggest challenges the industry is facing with regards to determining toxicology limits, assessing hazards, implementing risk procures, translating risk assessment into facility engineering, preventing and dealing with cross-contamination and adhering to GMP regulatory guidelines.

Attend this conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPI industry.

Explore HPAPI manufacturing with 8 big pharma from both the toxic substance and the employees’ perspective

Gain better understanding of human factors and ergonomics aspects and their role in improving production performance – NEW FOR 2020!

Deep dive into the oncology market and ADC production, the main driver of the HPAPI industry- NEW FOR 2020!

Learn what it takes to create a safety company culture and how to better train your employees on risk perception
 

Others Details

Speakers: Pascal Michoux, Vice President, Global EHS Teva api and Biologics, teva API Italy, William Hawkins, Manager Occupation Toxicology, GsK, Brian Edwards, Chair, Pharmaceutical Human Factors Group, CIeHf, Thomas Adam, Head of GQA Chemical APIs, Bayer AG, Ildiko Ziegler, QA Manager, Gedeon richter Time: 9:00 am - 5:00 pm